Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Cardiology/Vascular Diseases
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: COR Therapeutics, Key Pharmaceuticals
Approval Status: Approved May 1998
Treatment Area: For the treatment of acute coronary syndrome
For the treatment of patients with acute coronary syndrome
(UA/NQMI), including patients who are to be managed medically and
those undergoing percutaneous coronary intervention (PCI). In this
setting, Integrilin has been shown to decrease the rate of a
combined endpoint of death or new myocardial infarction.
For the treatment of patients undergoing PCI. In this setting,
Integrilin has been shown to decrease the rate of a combined
endpoint of death, new myocardial infarction, or need for urgent
intervention.
